D. Slamon, L. , B. Shak, S. Fuchs, H. Paton et al., Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-92, 2001.
DOI : 10.1056/NEJM200103153441101

D. Slamon, W. Eiermann, N. Robert, T. Pienkowski, M. Martin et al., Adjuvant Trastuzumab in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.365, issue.14, pp.1273-83, 2011.
DOI : 10.1056/NEJMoa0910383

URL : http://europepmc.org/articles/pmc3268553?pdf=render

T. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009.
DOI : 10.1056/NEJMoa0810699

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

J. Luo, N. Solimini, and S. Elledge, Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction, Cell, vol.136, issue.5, pp.823-860, 2009.
DOI : 10.1016/j.cell.2009.02.024

URL : https://doi.org/10.1016/j.cell.2009.08.006

Y. Lu, M. Muller, D. Smith, B. Dutta, K. Komurov et al., Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling, Oncogene, vol.30, issue.45, pp.4567-77, 2011.
DOI : 10.1158/0008-5472.CAN-08-0632

URL : http://www.nature.com/onc/journal/v30/n45/pdf/onc2011164a.pdf

M. Glickman and C. Sawyers, Converting Cancer Therapies into Cures: Lessons from Infectious Diseases, Cell, vol.148, issue.6, pp.1089-98, 2012.
DOI : 10.1016/j.cell.2012.02.015

URL : https://doi.org/10.1016/j.cell.2012.02.015

J. Downward, Targeting RAS signalling pathways in cancer therapy, Nature Reviews Cancer, vol.61, issue.1, pp.11-22, 2003.
DOI : 10.1038/356397a0

M. Laplante and D. Sabatini, mTOR Signaling in Growth Control and Disease, Cell, vol.149, issue.2, pp.274-93, 2012.
DOI : 10.1016/j.cell.2012.03.017

URL : https://doi.org/10.1016/j.cell.2012.03.017

A. Carracedo, L. Ma, J. Teruya-feldstein, F. Rojo, L. Salmena et al., Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, Journal of Clinical Investigation, vol.118, pp.3065-74, 2008.
DOI : 10.1172/JCI34739DS1

W. Chappell, L. Steelman, J. Long, R. Kempf, S. Abrams et al., mTOR inhibitors: rationale and importance to inhibiting these pathways in human health, Oncotarget, vol.2, pp.135-64, 2011.
DOI : 10.18632/oncotarget.240

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=240&path%5B%5D=353

J. Engelman, L. Chen, X. Tan, K. Crosby, A. Guimaraes et al., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nature Medicine, vol.13, issue.12, pp.1351-1357, 2008.
DOI : 10.1128/MCB.18.3.1379

URL : http://europepmc.org/articles/pmc2683415?pdf=render

G. Migliardi, F. Sassi, D. Torti, F. Galimi, E. Zanella et al., Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas, Clinical Cancer Research, vol.18, issue.9, pp.2515-2540, 2012.
DOI : 10.1158/1078-0432.CCR-11-2683

K. Saini, S. Loi, E. De-azambuja, O. Metzger-filho, M. Saini et al., Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer, Cancer Treatment Reviews, vol.39, issue.8, pp.935-981, 2013.
DOI : 10.1016/j.ctrv.2013.03.009

P. Bedard, J. Tabernero, F. Janku, Z. Wainberg, L. Paz-ares et al., A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors, Clinical Cancer Research, vol.21, issue.4, pp.730-738, 2015.
DOI : 10.1158/1078-0432.CCR-14-1814

A. Tolcher, K. Khan, M. Ong, U. Banerji, V. Papadimitrakopoulou et al., Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK, Clinical Cancer Research, vol.21, issue.4, pp.739-787, 2015.
DOI : 10.1158/1078-0432.CCR-14-1901

URL : http://clincancerres.aacrjournals.org/content/clincanres/21/4/739.full.pdf

A. Tolcher, J. Bendell, K. Papadopoulos, H. Burris, A. Patnaik et al., A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors, Annals of Oncology, vol.26, issue.1, pp.58-64, 2015.
DOI : 10.1634/theoncologist.2011-0111

T. Shimizu, A. Tolcher, K. Papadopoulos, M. Beeram, D. Rasco et al., The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer, Clinical Cancer Research, vol.18, issue.8, pp.2316-2341, 2012.
DOI : 10.1158/1078-0432.CCR-11-2381

R. Corcoran, H. Ebi, A. Turke, E. Coffee, M. Nishino et al., -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib, Cancer Discovery, vol.2, issue.3, pp.227-262, 2012.
DOI : 10.1158/2159-8290.CD-11-0341

A. Prahallad, C. Sun, S. Huang, D. Nicolantonio, F. Salazar et al., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, vol.15, issue.7388, pp.100-103, 2012.
DOI : 10.1016/j.ccr.2009.02.023

URL : https://iris.unito.it/retrieve/handle/2318/126889/19515/Prahallad_AuthorManuscript.pdf

J. Duncan, M. Whittle, K. Nakamura, A. Abell, A. Midland et al., Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer, Cell, vol.149, issue.2, pp.307-328, 2012.
DOI : 10.1016/j.cell.2012.02.053

M. Lee, A. Ye, A. Gardino, A. Heijink, P. Sorger et al., Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks, Cell, vol.149, issue.4, pp.780-94, 2012.
DOI : 10.1016/j.cell.2012.03.031

URL : https://doi.org/10.1016/j.cell.2012.03.031

T. Mazard, A. Causse, J. Simony, W. Leconet, N. Vezzio-vie et al., Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump, Molecular Cancer Therapeutics, vol.12, issue.10, pp.2121-2155, 2013.
DOI : 10.1158/1535-7163.MCT-12-0966

URL : https://hal.archives-ouvertes.fr/inserm-00861055

C. Gongora, N. Vezzio-vie, S. Tuduri, V. Denis, A. Causse et al., New Topoisomerase I mutations are associated with resistance to camptothecin, Molecular Cancer, vol.10, issue.1, p.64, 2011.
DOI : 10.1016/j.jmb.2004.03.077

URL : https://hal.archives-ouvertes.fr/inserm-00602236

W. Greco, G. Bravo, and J. Parsons, The search for synergy: a critical review from a response surface perspective, Pharmacol Rev, vol.47, pp.331-85, 1995.

J. Lehár, G. Zimmermann, A. Krueger, R. Molnar, J. Ledell et al., Chemical combination effects predict connectivity in biological systems, Molecular Systems Biology, vol.12, p.80, 2007.
DOI : 10.1042/bj3120145

J. Lehár, B. Stockwell, G. Giaever, and C. Nislow, Combination chemical genetics, Nature Chemical Biology, vol.89, issue.11, pp.674-81, 2008.
DOI : 10.1021/ci00060a003

J. Lehár, A. Krueger, W. Avery, A. Heilbut, L. Johansen et al., Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nature Biotechnology, vol.6, issue.7, pp.659-66, 2009.
DOI : 10.1016/S0022-5193(85)80176-4

B. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen et al., Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer, Cancer Cell, vol.19, issue.5, pp.575-86, 2011.
DOI : 10.1016/j.ccr.2011.04.008

URL : https://doi.org/10.1016/j.ccr.2011.04.008